Utility of NGAL and renal biomarker panel in predicting renal impairment, further decompensation and rehospitalization in acute decompensation and chronic heart failure patients: biomarker panel sub

  • Iyngkaran, Pupalan (Primary Chief Investigator (PCI))
  • Cameron, Peter (Chief Investigator (CI))
  • Krum, Henry (Chief Investigator (CI))

Project: Research

Project Details

Effective start/end date1/01/1031/12/10


  • Pfizer (Australia) (trading as Pfizer Australia Pty Limited)
  • Pfizer (Australia) (trading as Pfizer Australia Pty Limited): AUD48,864.00